# Newmarket Corp: financial statements, quarterly NEU · NYSE · CIK 1282637 · [Materials](/sectors/materials.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/neu.md) · [Financials](/companies/neu/financials.md) · [Filings](/companies/neu/filings.md) · [Insiders](/companies/neu/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/neu/financials.md?period=annual). ## Income statement | Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [643 d](/filings/0001282637-26-000005.md) | [697](/filings/0001282637-25-000010.md) | [710](/filings/0001282637-25-000016.md) | [725](/filings/0001282637-25-000024.md) | [655 d](/filings/0001282637-26-000005.md) | [701](/filings/0001282637-26-000009.md) | [699](/filings/0001282637-26-000016.md) | [690](/filings/0001282637-26-000020.md) | [635 d](/filings/0001282637-26-000005.md) | [670](/filings/0001282637-26-000009.md) | [747](/filings/0001282637-26-000016.md) | [717](/filings/0001282637-26-000020.md) | | Cost of revenue | $m | [466 d](/filings/0001282637-26-000005.md) | [480](/filings/0001282637-25-000010.md) | [492](/filings/0001282637-25-000016.md) | [481](/filings/0001282637-25-000024.md) | [447 d](/filings/0001282637-26-000005.md) | [465](/filings/0001282637-26-000009.md) | [478](/filings/0001282637-26-000016.md) | [481](/filings/0001282637-26-000020.md) | [445 d](/filings/0001282637-26-000005.md) | [449](/filings/0001282637-26-000009.md) | [505](/filings/0001282637-26-000016.md) | [494](/filings/0001282637-26-000020.md) | | Gross profit | $m | [177 d](/filings/0001282637-26-000005.md) | [216](/filings/0001282637-25-000010.md) | [218](/filings/0001282637-25-000016.md) | [244](/filings/0001282637-25-000024.md) | [208 d](/filings/0001282637-26-000005.md) | [236](/filings/0001282637-26-000009.md) | [221](/filings/0001282637-26-000016.md) | [210](/filings/0001282637-26-000020.md) | [191 d](/filings/0001282637-26-000005.md) | [221](/filings/0001282637-26-000009.md) | [242](/filings/0001282637-26-000016.md) | [222](/filings/0001282637-26-000020.md) | | Research and development | $m | [39.0 d](/filings/0001282637-26-000005.md) | [31.2](/filings/0001282637-25-000010.md) | [28.7](/filings/0001282637-25-000016.md) | [32.2](/filings/0001282637-25-000024.md) | [32.8 d](/filings/0001282637-26-000005.md) | [33.2](/filings/0001282637-26-000009.md) | [32.4](/filings/0001282637-26-000016.md) | [35.0](/filings/0001282637-26-000020.md) | [31.5 d](/filings/0001282637-26-000005.md) | [31.6](/filings/0001282637-26-000009.md) | [30.4](/filings/0001282637-26-000016.md) | [30.5](/filings/0001282637-26-000020.md) | | Selling, general and administrative | $m | [36.8 d](/filings/0001282637-26-000005.md) | [44.4](/filings/0001282637-25-000010.md) | [42.8](/filings/0001282637-25-000016.md) | [42.1](/filings/0001282637-25-000024.md) | [42.1 d](/filings/0001282637-26-000005.md) | [43.0](/filings/0001282637-26-000009.md) | [45.4](/filings/0001282637-26-000016.md) | [43.9](/filings/0001282637-26-000020.md) | [49.2 d](/filings/0001282637-26-000005.md) | [46.0](/filings/0001282637-26-000009.md) | [48.4](/filings/0001282637-26-000016.md) | [48.9](/filings/0001282637-26-000020.md) | | Operating income | $m | [101 d](/filings/0001282637-26-000005.md) | [141](/filings/0001282637-25-000010.md) | [147](/filings/0001282637-25-000016.md) | [170](/filings/0001282637-25-000024.md) | [133 d](/filings/0001282637-26-000005.md) | [160](/filings/0001282637-26-000009.md) | [143](/filings/0001282637-26-000016.md) | [131](/filings/0001282637-26-000020.md) | [110 d](/filings/0001282637-26-000005.md) | [143](/filings/0001282637-26-000009.md) | [164](/filings/0001282637-26-000016.md) | [143](/filings/0001282637-26-000020.md) | | Interest expense | $m | [7.1 d](/filings/0001282637-26-000005.md) | [15.7](/filings/0001282637-25-000010.md) | [15.9](/filings/0001282637-25-000016.md) | [14.2](/filings/0001282637-25-000024.md) | [11.6 d](/filings/0001282637-26-000005.md) | [10.7](/filings/0001282637-26-000009.md) | [10.7](/filings/0001282637-26-000016.md) | [8.4](/filings/0001282637-26-000020.md) | [9.9 d](/filings/0001282637-26-000005.md) | [8.8](/filings/0001282637-26-000009.md) | [8.8](/filings/0001282637-26-000016.md) | [8.0](/filings/0001282637-26-000020.md) | | Income tax | $m | [24.2 d](/filings/0001282637-26-000005.md) | [30.0](/filings/0001282637-25-000010.md) | [31.4](/filings/0001282637-25-000016.md) | [36.8](/filings/0001282637-25-000024.md) | [23.5 d](/filings/0001282637-26-000005.md) | [38.2](/filings/0001282637-26-000009.md) | [36.4](/filings/0001282637-26-000016.md) | [35.3](/filings/0001282637-26-000020.md) | [31.9 d](/filings/0001282637-26-000005.md) | [33.6](/filings/0001282637-26-000009.md) | [36.6](/filings/0001282637-26-000016.md) | [27.0](/filings/0001282637-26-000020.md) | | Net income | $m | [80.4 d](/filings/0001282637-26-000005.md) | [108](/filings/0001282637-25-000010.md) | [112](/filings/0001282637-25-000016.md) | [132](/filings/0001282637-25-000024.md) | [111 d](/filings/0001282637-26-000005.md) | [126](/filings/0001282637-26-000009.md) | [111](/filings/0001282637-26-000016.md) | [100](/filings/0001282637-26-000020.md) | [81.3 d](/filings/0001282637-26-000005.md) | [118](/filings/0001282637-26-000009.md) | [134](/filings/0001282637-26-000016.md) | [124](/filings/0001282637-26-000020.md) | | Diluted EPS | $ per share | not reported | [11.23](/filings/0001282637-25-000010.md) | [11.63](/filings/0001282637-25-000016.md) | [13.79](/filings/0001282637-25-000024.md) | not reported | [13.26](/filings/0001282637-26-000009.md) | [11.84](/filings/0001282637-26-000016.md) | [10.67](/filings/0001282637-26-000020.md) | not reported | [12.62](/filings/0001282637-26-000009.md) | [14.54](/filings/0001282637-26-000016.md) | [13.50](/filings/0001282637-26-000020.md) | | Basic EPS | $ per share | not reported | [11.23](/filings/0001282637-25-000010.md) | [11.63](/filings/0001282637-25-000016.md) | [13.79](/filings/0001282637-25-000024.md) | not reported | [13.26](/filings/0001282637-26-000009.md) | [11.84](/filings/0001282637-26-000016.md) | [10.67](/filings/0001282637-26-000020.md) | not reported | [12.62](/filings/0001282637-26-000009.md) | [14.54](/filings/0001282637-26-000016.md) | [13.50](/filings/0001282637-26-000020.md) | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax - Cost of revenue: us-gaap:CostOfGoodsAndServicesSold - Gross profit: us-gaap:GrossProfit - Research and development: us-gaap:ResearchAndDevelopmentExpense - Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense - Operating income: us-gaap:OperatingIncomeLoss - Interest expense: us-gaap:InterestExpense - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $m | [112](/filings/0001282637-25-000004.md) | [117](/filings/0001282637-24-000011.md) | [87.6](/filings/0001282637-24-000017.md) | [80.3](/filings/0001282637-24-000021.md) | [77.5](/filings/0001282637-26-000005.md) | [118](/filings/0001282637-25-000010.md) | [70.3](/filings/0001282637-25-000016.md) | [102](/filings/0001282637-25-000024.md) | [77.6](/filings/0001282637-26-000020.md) | [73.2](/filings/0001282637-26-000009.md) | [93.6](/filings/0001282637-26-000016.md) | [77.3](/filings/0001282637-26-000020.md) | | Current assets | $m | [1,040](/filings/0001282637-25-000004.md) | [1,119](/filings/0001282637-24-000011.md) | [1,115](/filings/0001282637-24-000017.md) | [1,138](/filings/0001282637-24-000021.md) | [1,030](/filings/0001282637-26-000005.md) | [1,124](/filings/0001282637-25-000010.md) | [1,068](/filings/0001282637-25-000016.md) | [1,101](/filings/0001282637-25-000024.md) | [1,060](/filings/0001282637-26-000020.md) | [1,065](/filings/0001282637-26-000009.md) | [1,150](/filings/0001282637-26-000016.md) | [1,159](/filings/0001282637-26-000020.md) | | Total assets | $m | [2,309](/filings/0001282637-25-000004.md) | [3,157](/filings/0001282637-24-000011.md) | [3,150](/filings/0001282637-24-000017.md) | [3,166](/filings/0001282637-24-000021.md) | [3,130](/filings/0001282637-26-000005.md) | [3,233](/filings/0001282637-25-000010.md) | [3,195](/filings/0001282637-25-000016.md) | [3,234](/filings/0001282637-25-000024.md) | [3,492](/filings/0001282637-26-000020.md) | [3,504](/filings/0001282637-26-000009.md) | [3,621](/filings/0001282637-26-000016.md) | [3,648](/filings/0001282637-26-000020.md) | | Current liabilities | $m | [364](/filings/0001282637-25-000004.md) | [391](/filings/0001282637-24-000011.md) | [420](/filings/0001282637-24-000017.md) | [402](/filings/0001282637-24-000021.md) | [374](/filings/0001282637-26-000005.md) | [396](/filings/0001282637-25-000010.md) | [402](/filings/0001282637-25-000016.md) | [410](/filings/0001282637-25-000024.md) | [419](/filings/0001282637-26-000020.md) | [417](/filings/0001282637-26-000009.md) | [511](/filings/0001282637-26-000016.md) | [471](/filings/0001282637-26-000020.md) | | Total liabilities | $m | [1,232](/filings/0001282637-25-000004.md) | [2,005](/filings/0001282637-24-000011.md) | [1,915](/filings/0001282637-24-000017.md) | [1,802](/filings/0001282637-24-000021.md) | [1,668](/filings/0001282637-26-000005.md) | [1,713](/filings/0001282637-25-000010.md) | [1,583](/filings/0001282637-25-000016.md) | [1,544](/filings/0001282637-25-000024.md) | [1,714](/filings/0001282637-26-000020.md) | [1,772](/filings/0001282637-26-000009.md) | [1,783](/filings/0001282637-26-000016.md) | [1,718](/filings/0001282637-26-000020.md) | | Long-term debt | $m | [644](/filings/0001282637-25-000004.md) | [1,279](/filings/0001282637-24-000011.md) | [1,173](/filings/0001282637-24-000017.md) | [1,085](/filings/0001282637-24-000021.md) | [971](/filings/0001282637-26-000005.md) | [991](/filings/0001282637-25-000010.md) | [842](/filings/0001282637-25-000016.md) | [783](/filings/0001282637-25-000024.md) | [883](/filings/0001282637-26-000020.md) | [940](/filings/0001282637-26-000009.md) | [855](/filings/0001282637-26-000016.md) | [830](/filings/0001282637-26-000020.md) | | Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Shareholders' equity | $m | [1,077](/filings/0001282637-26-000005.md) | [1,152](/filings/0001282637-25-000016.md) | [1,235](/filings/0001282637-25-000024.md) | [1,364](/filings/0001282637-25-000024.md) | [1,462](/filings/0001282637-26-000020.md) | [1,519](/filings/0001282637-26-000016.md) | [1,612](/filings/0001282637-26-000020.md) | [1,690](/filings/0001282637-26-000020.md) | [1,778](/filings/0001282637-26-000020.md) | [1,733](/filings/0001282637-26-000016.md) | [1,838](/filings/0001282637-26-000020.md) | [1,930](/filings/0001282637-26-000020.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Long-term debt: us-gaap:LongTermDebtNoncurrent - Current portion of debt: not reported - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [172 d](/filings/0001282637-26-000005.md) | [103](/filings/0001282637-25-000010.md) | [115 d](/filings/0001282637-25-000016.md) | [117 d](/filings/0001282637-25-000024.md) | [185 d](/filings/0001282637-26-000005.md) | [120](/filings/0001282637-26-000009.md) | [161 d](/filings/0001282637-26-000016.md) | [142 d](/filings/0001282637-26-000020.md) | [145 d](/filings/0001282637-26-000005.md) | [124](/filings/0001282637-26-000009.md) | [162 d](/filings/0001282637-26-000016.md) | [68.6 d](/filings/0001282637-26-000020.md) | | Capital expenditure | $m | [13.5 d](/filings/0001282637-26-000005.md) | [13.6](/filings/0001282637-25-000010.md) | [18.9](/filings/0001282637-25-000016.md) | [17.3](/filings/0001282637-25-000024.md) | [14.6 d](/filings/0001282637-26-000005.md) | [13.0](/filings/0001282637-26-000009.md) | [21.6](/filings/0001282637-25-000016.md) | [30.1](/filings/0001282637-25-000024.md) | [28.0 d](/filings/0001282637-26-000005.md) | [24.4](/filings/0001282637-26-000009.md) | [27.4 d](/filings/0001282637-26-000016.md) | [36.7 d](/filings/0001282637-26-000020.md) | | Dividends paid | $m | [21.6 d](/filings/0001282637-26-000005.md) | [24.0](/filings/0001282637-25-000010.md) | [24.0 d](/filings/0001282637-25-000016.md) | [24.0 d](/filings/0001282637-25-000024.md) | [23.9 d](/filings/0001282637-26-000005.md) | [26.1](/filings/0001282637-26-000009.md) | [25.8 d](/filings/0001282637-26-000016.md) | [25.8 d](/filings/0001282637-26-000020.md) | [28.2 d](/filings/0001282637-26-000005.md) | [28.0](/filings/0001282637-26-000009.md) | [27.6 d](/filings/0001282637-26-000016.md) | [27.6 d](/filings/0001282637-26-000020.md) | | Share repurchases | $m | [0.0 d](/filings/0001282637-26-000005.md) | [0.0](/filings/0001282637-25-000010.md) | [0.0 d](/filings/0001282637-25-000016.md) | [0.0 d](/filings/0001282637-25-000024.md) | [31.9 d](/filings/0001282637-26-000005.md) | [57.1](/filings/0001282637-26-000009.md) | [20.2 d](/filings/0001282637-26-000016.md) | [0.0 d](/filings/0001282637-26-000020.md) | [0.0 d](/filings/0001282637-26-000005.md) | [126](/filings/0001282637-26-000009.md) | [0.9 d](/filings/0001282637-26-000016.md) | [0.0 d](/filings/0001282637-26-000020.md) | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment, us-gaap:PaymentsToAcquireProductiveAssets - Dividends paid: us-gaap:PaymentsOfDividendsCommonStock - Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock ## Shares | Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | thousands of shares | [9,643](/filings/0001282637-24-000011.md) | [9,577](/filings/0001282637-24-000017.md) | [9,556](/filings/0001282637-24-000021.md) | [9,557](/filings/0001282637-25-000010.md) | [9,560](/filings/0001282637-25-000016.md) | [9,561](/filings/0001282637-25-000024.md) | [9,460](/filings/0001282637-26-000009.md) | [9,362](/filings/0001282637-26-000016.md) | [9,360](/filings/0001282637-26-000020.md) | [9,321](/filings/0001282637-26-000009.md) | [9,159](/filings/0001282637-26-000016.md) | [9,160](/filings/0001282637-26-000020.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 9,196,910 at 2026-09-30, from the cover of the [10-Q filed 2026-10-29](/filings/0001282637-26-000020.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 29, 2026, 19:40 ET. No prices; not investment advice.